There is growing concern regarding the risk of transfusion- transmitted (TT) hepatitis E. Since the first described case in 2006, several TT hepatitis E have been reported to the French hemovigilance network.
Eisai has disclosed the first clinical data (Phase 1) for its new early stage candidate for Alzheimer's disease, the beta-site...
Nexstim has completed its supplementary Phase III clinical trial, known as E-FIT (ELECTRIC FIELD NAVIGATED 1HZ RTMS FOR POST-STROKE MOTOR...
The risk of vitamin E deficiency is of primary concern in cystic fibrosis patients. However, early diagnosis and routine vitamin E supplementation can lead to its normal or even high levels.
The Phase III SELECT trial (Study 303) of E 7080 (lenvatinib), from Eisai, has met its primary endpoint in patients...
Eisai Co. and Purdue Pharma announced positive topline results from multiple studies of E 2006 (lemborexant), for sleep and wake...
A new study shows that AvidBiotics' antibacterial Purocin protein technology can be used to create a highly targeted bactericidal protein...
The incidence and prevalence of hepatitis E virus (HEV) infection has increased in many developed countries over the last decade. It has also been recognised that HEV infection can persist in immunosuppressed individuals...
Sporadic hepatitis E is an emerging indigenous disease in Europe induced by genotype 3 of the virus. While the disease takes an acute self-limited course in immunocompetent individuals, under immunocompromised...